CRESTOR Available for Pediatric Patients With Heterozygous Familial Hypercholesterolemia


October 16, 2009

AstraZeneca's CRESTOR (rosuvastatin calcium) is FDA indicated for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol.

CRESTOR, as an adjunct to diet in adult patients, significantly lowers LDL-C and has a significant effect on raising HDL-C and slowed the progression of atherosclerosis. CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also approved for pediatric patients 10 to 17 years of age with HeFH after failing an adequate trail of diet therapy. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to reduce cardiovascular morbidity and mortality.

The indication for use in children HeFH was cleared by the FDA in October 2009.

For more information: